Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors
暂无分享,去创建一个
M. Fakih | D. Trump | S. Strychor | W. Zamboni | M. Javle | N. Ramnath | J. Schwarz | P. Creaven | B. Zamboni | R. French | Trisha V. W. Repinski
[1] M. Fakih,et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies , 2005, Cancer Chemotherapy and Pharmacology.
[2] J. Yook,et al. A phase I / II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer , 2004 .
[3] K. Syrigos,et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Paccagnella,et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. , 2004, International journal of radiation oncology, biology, physics.
[5] M. Mazumdar,et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck , 2004, Anti-cancer drugs.
[6] B. Ryoo,et al. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer , 2004, British Journal of Cancer.
[7] M. Shibuya,et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Dae-Ho Lee,et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma , 2003, Cancer.
[9] N. Magné,et al. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] C. Boni,et al. 51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325) , 2003 .
[11] R. Ramlau,et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Tishler,et al. Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck , 2003, Cancer.
[13] M. Egorin,et al. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[14] David Miles,et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Shin,et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Janinis,et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. , 2000, American journal of clinical oncology.
[17] D. Figgitt,et al. Docetaxel: an update of its use in advanced breast cancer. , 2000, Drugs.
[18] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[19] A. Nixon,et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Leone,et al. Cisplatin Pharmacokinetics Using a Five‐Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors , 1995, Therapeutic drug monitoring.
[21] P. Apostoli,et al. Two‐Cycle Cisplatin Kinetics in Patients with Ovarian and Mammary Cancer , 1987, Therapeutic drug monitoring.
[22] P. Lohman,et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.
[23] M. Egorin,et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. , 1984, Cancer research.
[24] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[25] J. Doroshow,et al. Effects of storage on the binding of carboplatin to plasma proteins , 2004, Cancer Chemotherapy and Pharmacology.
[26] J. Yook,et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] K. Goa,et al. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. , 2001, Drugs.
[28] H. Lippert,et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[30] M. Piccart,et al. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] S. Lippard,et al. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.